You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
DERMABOND PRINEO Skin Closure System
DERMABOND PRINEO Skin Closure System
DERMABOND PRINEO Skin Closure System provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for SSIs.1,* DERMABOND PRINEO Skin Closure System was shown to provide statistically significant greater skin holding strength than skin staples or subcuticular 4-0 MONOCRYL (poliglecaprone 25) suture.2,**
Supporting Documentation
Product Support
Related Procedures
References
* Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium.
** In an ex-vivo study, more load in N was required to create a 3 ±1 mm gap between skin edges approximated with DERMABOND PRINEO System, than with subcuticular 4-0 MONOCRYL Suture or PROXIMATE ETHICON ENDO SURGERY skin staples (p=0.00).
1. Ethicon, Su 06TR071 Study Report for in vitro evaluation of microbial barrier properties of DERMABOND ProTape, December 2006, Data on File.
2. Ethicon, AST-2012-0290: Study to Compare the tissue holding strength of PRINEO skin closure system with conventional wound closure techniques, October 2012, Data on File.
© Johnson & Johnson Medical N.V., Belgium 2017.
© Johnson & Johnson Medical N.V., Belgium 2018-2019.
This site is published by Johnson & Johnson Medical N.V., Belgium which is solely responsible for its contents and is intended for EMEA audiences only. This site is intended for Healthcare Professionals. If you are a patient, it is important that you discuss information about the benefits and risks of products with your doctor.
Last updated February 22, 2019. The third-party trademarks used herein are trademarks of their respective owners. Data and usage fees may apply. See your carrier for more information.
*As of March 2017, per internal research conducted by Ethicon.